aTYR PHARMA (ATYR) Income from Continuing Operations (2014 - 2026)

aTYR PHARMA (ATYR) has reported Income from Continuing Operations for 13 consecutive years, with -$10.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations rose 46.47% year-over-year to -$10.9 million; the trailing twelve-month figure through Jun 2026 stood at -$63.9 million (up 8.8% YoY), and the FY2025 full-year result was -$77.6 million, down 14.3% from the prior year.
• Income from Continuing Operations improved to -$10.9 million in Q2 2026 per ATYR's latest filing, from -$11.5 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$8.0 million in Q4 2022 and bottomed at -$26.7 million in Q3 2025.
• Historically, Income from Continuing Operations has averaged -$15.0 million across 5 years, with a median of -$14.2 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations sank 100.74% in 2023, then jumped 46.47% in 2026.
• Over 5 years, Income from Continuing Operations stood at -$8.0 million in 2022, then tumbled by 100.74% to -$16.0 million in 2023, then rose by 0.87% to -$15.8 million in 2024, then rose by 6.47% to -$14.8 million in 2025, then increased by 26.47% to -$10.9 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$10.9 million, -$11.5 million, and -$14.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.